Kurzfassung

A randomized, double-masked, placebo-controlled exploratory
study to evaluate pharmacodynamics, safety and tolerability of
orally administered BI 1026706 for 12 weeks in patients with
mild visual impairment due to center-involved diabetic macular
edema (DME)